MSA Safety Reports 1st Elastomeric Respirator Without Exhalation Valve Is Approved by NIOSH

November 25, 2020

MSA Safety today reported that its next-generation Advantage 290 LS Air-Purifying Respirator (APR) is the first of its kind — designed without an exhalation valve — to receive approval from the National Institute for Occupational Safety and Health (NIOSH).

MSA Safety notes an elastomeric half-mask device, the Advantage 290 LS Respirator covers a wearer’s nose and mouth and utilizes twin filters to provide respiratory protection.

The U.S. Centers for Disease Control and Prevention (CDC) advises that NIOSH-approved respirators, including elastomeric half-mask respirators (EHMRs), are appropriate for use against SARS-CoV-2 in healthcare settings.  This established class of respirator can play a critical role in the nation’s response to COVID-19 and, importantly, bolster future readiness for similar microbial viruses and other emergencies.

In response to the global shortage of personal protective equipment (PPE), MSA has been working throughout the year with healthcare professionals to identify the respiratory protection needs of those on the front line of the pandemic.  Some applications within healthcare require a sterile environment, and one critical component to ensuring a sterile environment is source control. The Advantage 290 Respirator is the first EHMR to function without an exhalation valve, making it a new respiratory protection option that provides both personal protection and source control.  In addition, the new respirator gives healthcare facilities greater optionality and flexibility in developing their respiratory protection programs in accordance with Occupational Safety and Health Administration standards.

“Given the reusable design and nature of elastomeric respirators, there are many benefits of deploying a respiratory protection program that incorporates EHMRs, including cost-efficiency, reduced space requirements for PPE warehousing, and fewer concerns associated with PPE insecurities during a pandemic,” said Greg Martin, MSA Vice President of Product Strategy and Development.

Mr. Martin added that EHMRs also help mitigate concerns about product expiration while conferring additional benefits, like environmental sustainability, through extended use and reuse capability. “With the Advantage 290 model, our team went a step further and developed a respirator that has the potential to be an even more appealing option – today and down the road – for healthcare systems everywhere as they assess plans for the future and their own pandemic preparedness,” he said.

The Advantage 290 Respirator, which will be available for preorder in December 2020, will be produced at MSA Safety’s subsidiary operation in Jacksonville, N.C.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”